echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Announcement of Phase Ⅱ Clinical Data of KN046 Combined with Chemotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma

    Announcement of Phase Ⅱ Clinical Data of KN046 Combined with Chemotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma

    • Last Update: 2021-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 7, 2021, Corning Jereh Biopharmaceuticals (stock code: 9966.


    Esophageal cancer is one of the most common malignant tumors in the world.


    KN046-204 includes 3 cohorts, one of which enrolls patients with unresectable locally advanced, recurrent or metastatic ESCC who have not received systemic treatment in the past and confirmed by histology or cytology (ECOG PS 0-1 points)


    As of January 14, 2021, a total of 15 patients were enrolled in this cohort, all of whom were male, 52.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.